Further, reduced expression of DSG2 was found to be independently associated with a shorter biochemical recurrence, highlighting the potential utility of DSG2 expression as a prognostic biomarker of prostate cancer aggressiveness. This evidence concerns the gene DSG2 and prostate cancer.